CWA
DFTX

Clearview Wealth Advisors’s Definium Therapeutics DFTX Stock Holding History

Clearview Wealth Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-66
Closed -$236 – 419
2023
Q2 		$236 Hold
66
– – ﹤0.01% 656
2023
Q1 		$209 Hold
66
– – ﹤0.01% 646
2022
Q4 		$145 Hold
66
– – ﹤0.01% 600
2022
Q3 		$0 Sell
66
-1
-1% -$10 ﹤0.01% 616
2022
Q2 		$1K Buy
+67
New +$848 ﹤0.01% 547

Other funds holding DFTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Clearview Wealth Advisors's DFTX Position: Q3 2023 in Review

Clearview Wealth Advisors sold out of Definium Therapeutics (DFTX) in Q3 2023, closing a stake of 66 shares — an estimated $236 sold.

Clearview Wealth Advisors first reported a position in DFTX in Q2 2022 and held it in 5 quarters. The position peaked at $1K in Q2 2022. 93 funds tracked by Wall St. Rank hold DFTX as of Q3 2023.

  • Clearview Wealth Advisors reported no remaining Definium Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Clearview Wealth Advisors sold 66 Definium Therapeutics shares in Q3 2023, an estimated $236.
  • Clearview Wealth Advisors first reported a position in Definium Therapeutics in Q2 2022 and held it in 5 quarters.
  • Clearview Wealth Advisors's Definium Therapeutics position peaked at $1K in Q2 2022.
  • 93 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2023.

Based on Clearview Wealth Advisors's 13F filing for Q3 2023, filed 30 Oct 2023.